Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Evaluate the Safety and Pharmacokinetic of SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Crcinoma: an Open-label, Single-arm, Dose Escalation Exploratory Study

NCT06384482 is registered in ClinicalTrials.gov with Shanghai Simnova Biotechnology Co.,Ltd. as lead sponsor.

NCT NCT06384482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06384482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Evaluate the Safety and Pharmacokinetic of SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Crcinoma: an Open-label, Single-arm, Dose Escalation Exploratory Study
Lead sponsor
Shanghai Simnova Biotechnology Co.,Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
April 30, 2024
Completion date
December 30, 2025
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent/refractory small cell lung cancer lung large cell neuroendocrine carcinoma